CYCC vs. GHSI, RNAZ, MBRX, ERNA, MNPR, GRTX, AEZS, ABVC, VAXX, and OGEN
Should you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Guardion Health Sciences (GHSI), TransCode Therapeutics (RNAZ), Moleculin Biotech (MBRX), Eterna Therapeutics (ERNA), Monopar Therapeutics (MNPR), Galera Therapeutics (GRTX), Aeterna Zentaris (AEZS), ABVC BioPharma (ABVC), Vaxxinity (VAXX), and Oragenics (OGEN). These companies are all part of the "pharmaceutical preparations" industry.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Guardion Health Sciences (NASDAQ:GHSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.2% of Guardion Health Sciences shares are owned by institutional investors. 8.0% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of Guardion Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cyclacel Pharmaceuticals presently has a consensus target price of $11.00, indicating a potential upside of 316.67%. Given Cyclacel Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Guardion Health Sciences.
Cyclacel Pharmaceuticals received 125 more outperform votes than Guardion Health Sciences when rated by MarketBeat users. However, 67.39% of users gave Guardion Health Sciences an outperform vote while only 48.95% of users gave Cyclacel Pharmaceuticals an outperform vote.
Guardion Health Sciences has higher revenue and earnings than Cyclacel Pharmaceuticals. Guardion Health Sciences is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Guardion Health Sciences has a net margin of -16.69% compared to Cyclacel Pharmaceuticals' net margin of -4,401.34%. Guardion Health Sciences' return on equity of -77.29% beat Cyclacel Pharmaceuticals' return on equity.
In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 2 articles in the media. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Guardion Health Sciences' score of 0.25 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.
Cyclacel Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Guardion Health Sciences has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Summary
Cyclacel Pharmaceuticals beats Guardion Health Sciences on 9 of the 17 factors compared between the two stocks.
Get Cyclacel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclacel Pharmaceuticals Competitors List
Related Companies and Tools
